Price Change to Note: Chromadex Corp’s Stock Is Sell After Touching 1 Year Low

Price Change to Note: Chromadex Corp's Stock Is Sell After Touching 1 Year Low

The stock of Chromadex Corp (NASDAQ:CDXC) hit a new 52-week low and has $2.08 target or 13.00% below today’s $2.39 share price. The 5 months bearish chart indicates high risk for the $86.07 million company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $2.08 price target is reached, the company will be worth $11.19 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 85,759 shares traded hands. Chromadex Corp (NASDAQ:CDXC) has declined 40.79% since April 1, 2016 and is downtrending. It has underperformed by 42.01% the S&P500.

Analysts await Chromadex Corp (NASDAQ:CDXC) to report earnings on November, 10.

According to Zacks Investment Research, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex’s core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company’s main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico.”

More important recent Chromadex Corp (NASDAQ:CDXC) news were published by: Reuters.com which released: “BRIEF-Chromadex Corp says Chromadex Inc entered into second addendum to ni…” on September 19, 2016, also Globenewswire.com published article titled: “ChromaDex Launches New Patented Ingredient – IMMULINA(TM) – a Powerful …”, Globenewswire.com published: “ChromaDex Corp. (Nasdaq: CDXC) to Ring The Nasdaq Stock Market Opening Bell” on May 05, 2016. More interesting news about Chromadex Corp (NASDAQ:CDXC) was released by: Globenewswire.com and their article: “ChromaDex and Collaborators Report Unexpected Discovery of Novel Biomarkers of …” with publication date: August 12, 2015.

CDXC Company Profile

Chromadex Corporation, incorporated on June 19, 2008, and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control services and products to the natural products industry. The Firm allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Firm operates through three divisions: Ingredients, Core standards and contract services, and Scientific and regulatory consulting. Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients to the manufacturers of consumer products in various industries, including the nutritional supplement, food and beverage, and animal health industries. Core standards and contract services segment includes supply of phytochemical reference standards, which are small quantities of plant compounds used to research an array of attributes, reference materials and related contract services. Scientific and regulatory consulting segment provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment